Artimplant AB : New Head of Research and Development at Artimplant

Katrin Gisselfält is stepping down as Head of Research and Development at Artimplant to take up a position at another company.

Lars Peterson will take over as Head of Research and Development until a suitable permanent solution has been found. Lars Peterson has been a member of the Artimplant Board of Directors since 2011. He is also emeritusprofessor at the Sahlgrenska Academy, Gothenburg University, and he conducts research into tissue regeneration.

CEO Kjell Thörnbring states that with Lars Peterson as Head of Research and Development, the company will be reinforced considerably. “His background as an internationally recognized and highly valued orthopedic surgeon will add a dimension that has not existed at Artimplant for many years. As an innovator and co-founder of the company, Lars Peterson represents a link back to the original concept of satisfying medical needs. I’m extremely pleased that he is willing and able to take on the task of developing and reinforcing the company’s products and services.”


For additional information, please contact:
Kjell Thörnbring, CEO, phone +46 (0)703 11 90 25,

Further information is available at To subscribe to future press releases please go to

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company’s business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company’s filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on August 21, 2012 at 4:30 PM (Swedish time).

The following files are available for download:


Josh Sandberg

Josh Sandberg is the President of Ortho Sales Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *